BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1119 related articles for article (PubMed ID: 30334814)

  • 1. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
    Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR
    J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
    Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
    Chen Z; Wu D; Thomas-Ahner JM; Lu C; Zhao P; Zhang Q; Geraghty C; Yan PS; Hankey W; Sunkel B; Cheng X; Antonarakis ES; Wang QE; Liu Z; Huang TH; Jin VX; Clinton SK; Luo J; Huang J; Wang Q
    Proc Natl Acad Sci U S A; 2018 Jun; 115(26):6810-6815. PubMed ID: 29844167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.
    Zadra G; Ribeiro CF; Chetta P; Ho Y; Cacciatore S; Gao X; Syamala S; Bango C; Photopoulos C; Huang Y; Tyekucheva S; Bastos DC; Tchaicha J; Lawney B; Uo T; D'Anello L; Csibi A; Kalekar R; Larimer B; Ellis L; Butler LM; Morrissey C; McGovern K; Palombella VJ; Kutok JL; Mahmood U; Bosari S; Adams J; Peluso S; Dehm SM; Plymate SR; Loda M
    Proc Natl Acad Sci U S A; 2019 Jan; 116(2):631-640. PubMed ID: 30578319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.
    Zhu Y; Sharp A; Anderson CM; Silberstein JL; Taylor M; Lu C; Zhao P; De Marzo AM; Antonarakis ES; Wang M; Wu X; Luo Y; Su N; Nava Rodrigues D; Figueiredo I; Welti J; Park E; Ma XJ; Coleman I; Morrissey C; Plymate SR; Nelson PS; de Bono JS; Luo J
    Eur Urol; 2018 May; 73(5):727-735. PubMed ID: 28866255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
    Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
    Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
    Kohli M; Ho Y; Hillman DW; Van Etten JL; Henzler C; Yang R; Sperger JM; Li Y; Tseng E; Hon T; Clark T; Tan W; Carlson RE; Wang L; Sicotte H; Thai H; Jimenez R; Huang H; Vedell PT; Eckloff BW; Quevedo JF; Pitot HC; Costello BA; Jen J; Wieben ED; Silverstein KAT; Lang JM; Wang L; Dehm SM
    Clin Cancer Res; 2017 Aug; 23(16):4704-4715. PubMed ID: 28473535
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Zhu Y; Silberstein JL; Taylor MN; Maughan BL; Denmeade SR; Pienta KJ; Paller CJ; Carducci MA; Eisenberger MA; Luo J
    J Clin Oncol; 2017 Jul; 35(19):2149-2156. PubMed ID: 28384066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
    Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
    Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy.
    Liu VWS; Yau WL; Tam CW; Yao KM; Shiu SYW
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Zhu Y; Dalrymple SL; Coleman I; Zheng SL; Xu J; Hooper JE; Antonarakis ES; De Marzo AM; Meeker AK; Nelson PS; Isaacs WB; Denmeade SR; Luo J; Brennen WN; Isaacs JT
    Oncogene; 2020 Nov; 39(45):6935-6949. PubMed ID: 32989253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
    Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS
    Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
    Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
    Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
    Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
    Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
    Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 56.